A Prospective Comparison of Two Regimens of Prophylactic Antibiotics in Abdominal Trauma

Microbiological Profile and Antimicrobial Susceptibility in Surgical Site Infections Following Hollow Viscus Injury

“…Nevertheless, in contrast to ampicillin/sulbactam, broad-spectrum empiric therapy for 24 h with a second generation cephalosporin or piperacillin/ tazobactam appears to be adequate. 3,8,34 However, ESBLproducing microorganisms should be anticipated, since recent data has demonstrated that both hospital and community-acquired intra-abdominal infections can be caused by these resistant pathogens. 20,21 Empiric coverage of Enterococci remains controversial.…”

“…[1][2][3][4][5][6][7][8][9][10] There is an extensive body of literature examining the risk factors associated with an SSI following trauma, which include gross contamination by colonic content, advanced age, requirement for blood product transfusion, and concomitant stomach injury. 1,2,[5][6][7]9 Multiple investigations have also attempted to assess the efficacy of various antimicrobial regimens aimed at reducing the incidence of postoperative infections after abdominal surgery.…”

“…1,2,[5][6][7]9 Multiple investigations have also attempted to assess the efficacy of various antimicrobial regimens aimed at reducing the incidence of postoperative infections after abdominal surgery. 3,4,[10][11][12][13][14][15][16][17][18][19] A clear understanding of the microbiological profile of SSI after HVI is important for guiding empiric therapy for these injuries. This is made more difficult by the fact that this is a fast-moving target.…”

Microbiology and management of intra‐abdominal infections in children

“…The efficacy of single‐agent therapy was demonstrated in the management of intra‐abdominal infection following trauma. Single‐agent therapy with either cefoxitin or moxa­lactam was found to be equally effective as clindamycin plus an aminoglycoside, 43−48 and superior to cephalosporins less active against B. fragilis group 44−46 . Other studies illustrated that single‐agent therapy with carbapenems (i.e.…”